Track 1: Oncology Versus Traditional Pharmacy in Treatment Decision-making for Multiple Myeloma
Track 2: Value-based and Alternative Advanced Managed Care Oncology Benefit Strategies

Release date: August 15, 2011
Expiration date: February 28, 2013
Estimated time to complete activity: 1.0 hour for Track 1; 1.0 hour for Track 2

Target Audience

Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations
Managed care–affiliated care team members involved with patient evaluation, education, and follow-up for patients with a cancer such as multiple myeloma including: physicians, pharmacists, nurses, and case managers

Purpose Statement

During the last two decades, managed care organizations (MCOs) have spent a considerable amount of time and resources managing prescription drug costs for large chronic disease categories. Because managed care leaders have identified oncology drugs and biologics as priority areas for managing costs, education is needed to obtain the knowledge to develop and implement new strategies, coordinate oncology care through case management, educate patients about treatment with current and emerging cancer drugs, and collaborate effectively with specialty pharmacy management. Utilizing the management of multiple myeloma as an example, this activity will recommend emerging oncology pharmacy management strategies and methods for managed care professionals to implement within their current setting as well as extrapolate to other types of cancer as needed.

Educational Objectives (Track 1)
After completing this activity, the participant should be better able to:

Describe managed care strategies and methods for oncology pharmacy management versus traditional pharmacy management for chronic illnesses
Explain the use of decision support tools that utilize evidence-based treatment management plans for patients with multiple myeloma in a managed care setting

Educational Objectives (Track 2)
After completing this activity, the participant should be better able to:

Identify techniques for managed care organizations to determine the cost-effectiveness and survival benefits of multiple myeloma therapies
Explain emerging oncology pharmacy benefit management programs and methods that MCOs can implement to improve overall patient outcomes

Distinguished Faculty (Track 1)


	David G. Frame, PharmD Hematology/Oncology and Bone Marrow Specialist University of Michigan Health System Assistant Professor of Pharmacy University of Michigan Assistant Professor of Pharmacology and Medicine Rush University Click here for biography


	David H. Vesole, MD, PhD Co-Division Chief of Myeloma The John Theurer Cancer Center at Hackensack University Medical Center (HUMC) Director, Myeloma Research Northern New Jersey Cancer Associates Click here for biography

Distinguished Faculty (Track 2)


	Jeffrey D. Dunn, PharmD, MBA Formulary and Contract Manager Select Health Click here for biography


	C. Daniel Mullins, PhD Professor and Chair The Pharmaceutical Health Services Research Department University of Maryland – School of Pharmacy Click here for biography

Activity Agenda (Track 1)

Implementation of an Evidence-based Treatment Process for Patients With Multiple Myeloma in a Managed Care Setting
David H. Vesole, MD, PhD
Traditional Pharmacy Management Versus Oncology Pharmacy Management: Analyzing the Similarities and the Differences
David G. Frame, PharmD

Activity Agenda (Track 2)

Pharmacoeconomic Analyses and Oncology Pharmacy: Optimizing Multiple Myeloma Value for Patients and Plans
C. Daniel Mullins, PhD
Oncology Pharmacy Management Techniques: Emerging Strategies for Managed Care Professionals
Jeffrey D. Dunn, PharmD, MBA

Continuing Education (Track 1)

Statement of Credit-Participants who successfully complete this knowledge-based activity (including scoring at least 70% on the learning assessment and completing and submitting the evaluation form) will be issued a statement of credit. This statement of credit will be made available immediately.


	Physicians. The Meniscus Educational Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Meniscus Educational Institute designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


	Nurses. This activity for 1.0 contact hours is provided by the Meniscus Educational Institute.

The Meniscus Educational Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Accreditation refers to recognition of educational activities only and does not imply approval or endorsement by the Meniscus Educational Institute or the American Nurses Credentialing Center's Commission on Accreditation of any product mentioned.

Provider approved by the California Board of Registered Nursing, Provider No. 13164, for 1.0 contact hours.


	Pharmacists. This educational activity is sponsored by the Meniscus Educational Institute. The Meniscus Educational Institute is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The ACPE Universal Activity Number assigned to this program, for 1.0 contact hours (0.10 CEUs), is 0429-9999-11-006-H04-P.

Continuing Education (Track 2)


	Physicians. The Meniscus Educational Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


	Nurses. This activity for 1.0 contact hours is provided by the Meniscus Educational Institute.

The Meniscus Educational Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Provider approved by the California Board of Registered Nursing, Provider No. 13164, for 1.0 contact hours.


	Pharmacists. This educational activity is sponsored by the Meniscus Educational Institute. The Meniscus Educational Institute is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The ACPE Universal Activity Number assigned to this program, for 1.0 contact hours (0.10 CEUs), is 0429-9999-11-007-H04-P.

Financial Disclosures

All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity. All faculty have been offered a modest honorarium from the accredited provider for their participation in this activity.

Jeffrey D. Dunn, PharmD, MBA, Faculty, serves as a consultant or advisor for ChemGenex, Genomic Health, and Celgene Corporation.
David G. Frame, PharmD, Faculty, serves as a consultant or advisor for and receives honoraria from Celgene Corporation and Millennium Pharmaceuticals.
C. Daniel Mullins, PhD, Faculty, serves as a consultant or advisor for Amgen Inc., Bayer Corporation, Bristol-Myers Squibb, Cubist Pharmaceuticals Inc., Eisai Inc., Genentech Inc., Novartis Pharmaceuticals, Pfizer Inc. and sanofi-aventis. He also receives grant or research funding from Bayer, Novartis, Pfizer, and sanofi-aventis.
David H. Vesole, MD, PhD, Faculty, serves as a consultant or advisor for Celgene Corporation and receives honoraria from Celgene Corporation, Millennium Pharmaceuticals, and Onyx.
Karen Abbas, RN, MS, AOCN, Nurse Planner, has nothing to disclose.
Carol Balmer, PharmD, BCOP, Education Committee Reviewer, has nothing to disclose.
Paul B. Gilman, MD, Education Committee Reviewer, has nothing to disclose.
Sandra E. Kurtin, RN, MS, AOCN, ANP-C, Education Committee Reviewer, receives honoraria from Celgene Corporation and Novartis Pharmaceuticals.
Laura Wood, RN, MSN, OCN, Education Committee Reviewer, receives honoraria from Bayer/Onyx, Genentech Inc., Novartis Pharmaceuticals, and Pfizer Inc.
Steve Casebeer, MBA, Planner, has nothing to disclose.

Disclaimer

This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Meniscus Educational Institute educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by MEI or the companies providing educational grant support of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

There are no fees for participating in these activities.